Showing results (21-30 of 67) with videos related to
Sort By:
Pageof 7
Journal of Pharmaceutical Sciences|March 1, 1992
Factors affecting in vitro protein binding of etoposide in humansR A Fleming, W E Evans, S G Arbuck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1990
Changes in the clearance of total and unbound etoposide in patients with liver dysfunctionC F Stewart, S G Arbuck, R A Fleming, et al.Clinical Pharmacology and Therapeutics|January 1, 1989
Altered protein binding of etoposide in patients with cancerC F Stewart, J A Pieper, S G Arbuck, et al.Clinical Pharmacology and Therapeutics|October 1, 1991
Relation of systemic exposure to unbound etoposide and hematologic toxicityC F Stewart, S G Arbuck, R A Fleming, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1986
Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancerS G Arbuck, F Trave, H O Douglass, et al.Stem Cells (Dayton, Ohio)|January 1, 1994
Clinical development of anticancer agents from natural productsD R Parkinson, S G Arbuck, T Moore, et al.Journal of the National Cancer Institute|August 6, 1997
Accelerated titration designs for phase I clinical trials in oncologyR Simon, B Freidlin, L Rubinstein, et al.Seminars in Oncology|August 1, 1993
Clinical toxicities encountered with paclitaxel (Taxol)E K Rowinsky, E A Eisenhauer, V Chaudhry, et al.Cancer|June 1, 1990
A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinomaS G Arbuck, Y Silk, H O Douglass, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Clinical trial designs for cytostatic agents: are new approaches needed?E L Korn, S G Arbuck, J M Pluda, et al.Pageof 7